Contrasting Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD)

PolyPid (NASDAQ:PYPD) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for PolyPid and Beta Bionics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0	0	3	1	3.25
Beta Bionics	0	3	5	1	2.78

PolyPid currently has a consensus target price of $11.33, indicating a potential upside of 307.67%. Beta Bionics has a consensus target price of $24.83, indicating a potential upside of 88.85%. Given PolyPid’s stronger consensus rating and higher possible upside, research analysts clearly believe PolyPid is more favorable than Beta Bionics.

Valuation and Earnings

This table compares PolyPid and Beta Bionics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($4.97)	-0.56
Beta Bionics	$53.03 million	10.63	N/A	N/A	N/A

Beta Bionics has higher revenue and earnings than PolyPid.

Profitability

This table compares PolyPid and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-624.10%	-129.28%
Beta Bionics	N/A	N/A	N/A

Institutional and Insider Ownership

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.